First in human (FIH) clinical trials of bispecific immunostimulatory antibodies commonly require a low starting dose based on a minimum anticipated biological effect level (MABEL) approach. To ...

Assessing the pharmacokinetics (PK) of antibody-drug conjugates (ADCs) in both preclinical and clinical settings is crucial for their development. Biotransformation processes can lead to the creation ...

Having a robust immunogenicity assay for accurate evaluation of ADA in animal models is important for enabling effective decision-making during development. Learn how a robust anti-drug antibody assay ...

The Assay Focuses Its Inner Eye on Complex Biology, Through 3D Models, Reporter Genes, Ubiquitin Traps, and More If the eye is the lamp of the body, the assay is a searchlight that illuminates complex ...